Discovery Talks are the research community's international seminar series. Featuring influential research leaders from around the globe, the series promotes knowledge exchange, fosters international collaborations and showcases the latest innovations in research.
The Childhood Diseases Theme at BC Children's Hospital presents:


CAR T cells for Cancer:
Current Concepts and Future Prospects  

Crystal L. Mackall, MD
Endowed Professor of Pediatrics and Medicine, Stanford University;
 Founding Director, Stanford Center for Cancer Cell Therapy;
Associate Director, Stanford Cancer Institute;
Director, Parker Institute for Cancer Immunotherapy at Stanford  



The seminar was scheduled for Tuesday, June 12, 2018, 2 - 3 p.m. at the Chan Centre for Family Health Education (Map), BC Children's Hospital Research Institute. 

Missed the event? You can watch the seminar online.


Discovery Talks is accredited as a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. CME credits are available for all participants.

About the Speaker

During a 10-year tenure as Chief of the Pediatric Oncology Branch at the National Cancer Institute (NCI), Dr. Crystal L. Mackall, MD, built an internationally recognized translational research program spanning basic studies of T cell homeostasis and tumor immunology, and clinical trials of immune based therapies for cancer. Her work is credited with identifying an essential role for the thymus in human T cell regeneration and discovering IL-7 as the master regulator of T cell homeostasis. 

Dr. Mackall has led numerous first-in-human and first-in-child clinical trials spanning dendritic cell vaccines, cytokines, and adoptive immunotherapy using NK cells and genetically modified T cells. Her group was among the first to demonstrate impressive activity of CD19-CAR in pediatric leukemia, to demonstrate activity of the CD22-CAR in childhood leukemia, and to identify T cell exhaustion as a major factor limiting the efficacy of this novel class of therapeutics. 

At Stanford, Dr. Mackall launched one of the first trials utilizing a bispecific CAR aimed at offsetting immune escape. Her clinical trials are notable for the incorporation of deep biologic endpoints that further our understanding of the basis for success and failure of the agent under study. She has published over 170 manuscripts in peer-reviewed journals and serves in numerous leadership positions, including Co-Leader of the St. Baldrick’s-StandUp2Cancer Pediatric Dream Team, Chair of the AACR Pediatric Cancer Working Group, and Leader of the NCI Pediatric Cancer Immunotherapy Trials Network. She is also Board Certified in Pediatrics and Internal Medicine. 

Video recordings of previous lectures are available online: Video Library. These may be useful for classes, or of interest to those who are unable to attend events. 

For more information, contact please